首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1523301

纖維肌發育不良治療市場報告：2030 年趨勢、預測與競爭分析

Fibromuscular Dysplasia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2024年07月01日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

纖維肌性發育不良治療的趨勢與預測

預計 2024 年至 2030 年，全球纖維肌性發育不良治療市場將以 7.3% 的複合年成長率成長。該市場的主要促進因素是全球人口中高血壓發病率的增加和吸煙率的上升。全球纖維肌性發育不良治療市場的未來看起來充滿希望，醫院藥局、零售藥局和線上藥局市場充滿機會。

纖維肌性發育不良治療的細分趨勢

包含按藥物類別、通路和地區分類的全球纖維肌性發育不良治療預測。

纖維肌發育不良治療市場洞察

Lucintel 預測，血管收縮素II 受體拮抗劑預計將在預測期內達到最高成長。

醫院藥房仍然是市場上最大的部分。

預計北美地區在預測期內將出現最高的成長。

常問問題

Q1.市場成長預測是多少：

A1. 2024 年至 2030 年，全球纖維肌性發育不良治療市場預計將以 7.3% 的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要促進因素是全球人口中高血壓發病率的增加和吸煙率的上升。

Q3.市場的主要細分市場是：

A3. 纖維肌性發育不良治療市場的未來性廣闊，醫院藥局、零售藥局、網路藥局市場都有機會。

Q4.市場的主要企業是：

A4. 生產纖維肌性發育不良治療藥物的主要企業如下：

ALVOGEN
Aspen Surgical Products
AstraZeneca
B. Braun Melsungen
Bayer Healthcare Pharmaceuticals
Becton
Dickinson & Company
Pfizer
Sanofi-Aventis
Smith & Nephew

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預測，醫院藥局將在預測期內達到最高成長。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 預計北美地區在預測期內將出現最高成長。

Q7. 可以客製化報告嗎？

A7。

宏觀經濟趨勢（2018-2023）與預測（2024-2030）
全球纖維肌發育不良治療市場趨勢（2018-2023）與預測（2024-2030）
按藥物類別分類的全球纖維肌發育不良治療市場
- 血管張力素轉化酵素抑制劑
- 血管收縮素II受體阻斷劑
- 利尿劑
- 鈣離子通道阻斷劑
- BETA阻斷劑
按分銷管道分類的全球纖維肌發育不良治療市場
- 醫院藥房
- 零售藥房
- 網路藥房

第4章 2018-2030年區域市場趨勢及預測分析

全球纖維肌發育不良治療市場（按地區）
北美纖維肌性發育不良治療市場
歐洲纖維肌性發育不良治療市場
亞太地區纖維肌發育不良治療市場
其他區域纖維肌發育不良治療市場

第5章競爭分析

產品系列分析
營運整合
波特五力分析

第6章成長機會與策略分析

成長機會分析
- 按藥物類別分類的全球纖維肌發育不良治療市場成長機會
- 全球纖維肌發育不良治療市場成長機會（按分銷管道）
- 全球纖維肌發育不良治療市場按地區成長機會
全球纖維肌性發育不良治療市場的新興趨勢
戰略分析
- 新產品開發
- 擴大全球纖維肌發育不良治療市場的產能
- 全球纖維肌性發育不良治療市場的合併、收購與合資企業
- 認證和許可

第7章主要企業概況

ALVOGEN
Aspen Surgical Products
AstraZeneca
B. Braun Melsungen
Bayer Healthcare Pharmaceuticals
Becton
Dickinson & Company
Pfizer
Sanofi-Aventis
Smith & Nephew

簡介目錄

Fibromuscular Dysplasia Treatment Trends and Forecast

The future of the global fibromuscular dysplasia treatment market looks promising with opportunities in the hospitals pharmacies, retail pharmacies, and online pharmacies markets. The global fibromuscular dysplasia treatment market is expected to grow with a CAGR of 7.3% from 2024 to 2030. The major drivers for this market are increasing incidence of hypertension across the global population and rising occurrence of smoking.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Fibromuscular Dysplasia Treatment by Segment

The study includes a forecast for the global fibromuscular dysplasia treatment by drug class, distribution channel, and region.

Fibromuscular Dysplasia Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Receptor Blockers
Diuretics
Calcium Channel Blockers
Beta-Blockers
Others

Fibromuscular Dysplasia Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

Fibromuscular Dysplasia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Fibromuscular Dysplasia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies fibromuscular dysplasia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the fibromuscular dysplasia treatment companies profiled in this report include-

ALVOGEN
Aspen Surgical Products
AstraZeneca
B. Braun Melsungen
Bayer Healthcare Pharmaceuticals
Becton
Dickinson & Company
Pfizer
Sanofi-Aventis
Smith & Nephew

Fibromuscular Dysplasia Treatment Market Insights

Lucintel forecasts that angiotensin II receptor blockers is expected to witness the highest growth over the forecast period.

Within this market, hospitals pharmacies will remain the largest segment.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Fibromuscular Dysplasia Treatment Market

Market Size Estimates: Fibromuscular dysplasia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Fibromuscular dysplasia treatment market size by drug class, distribution channel, and region in terms of value ($B).

Regional Analysis: Fibromuscular dysplasia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, distribution channels, and regions for the fibromuscular dysplasia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the fibromuscular dysplasia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for fibromuscular dysplasia treatment market?

Answer: The global fibromuscular dysplasia treatment market is expected to grow with a CAGR of 7.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the fibromuscular dysplasia treatment market?

Answer: The major drivers for this market are increasing incidence of hypertension across the global population and rising occurrence of smoking.

Q3. What are the major segments for fibromuscular dysplasia treatment market?

Answer: The future of the fibromuscular dysplasia treatment market looks promising with opportunities in the hospitals pharmacies, retail pharmacies, and online pharmacies markets.

Q4. Who are the key fibromuscular dysplasia treatment market companies?

Answer: Some of the key fibromuscular dysplasia treatment companies are as follows:

ALVOGEN
Aspen Surgical Products
AstraZeneca
B. Braun Melsungen
Bayer Healthcare Pharmaceuticals
Becton
Dickinson & Company
Pfizer
Sanofi-Aventis
Smith & Nephew

Q5. Which fibromuscular dysplasia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that hospitals pharmacies is expected to witness the highest growth over the forecast period.

Q6. In fibromuscular dysplasia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the fibromuscular dysplasia treatment market by drug class (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, beta-blockers, and others), distribution channel (hospitals pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Fibromuscular Dysplasia Treatment Market : Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Fibromuscular Dysplasia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Fibromuscular Dysplasia Treatment Market by Drug Class
- 3.3.1: Angiotensin-Converting Enzyme Inhibitors
- 3.3.2: Angiotensin II Receptor Blockers
- 3.3.3: Diuretics
- 3.3.4: Calcium Channel Blockers
- 3.3.5: Beta-Blockers
3.4: Global Fibromuscular Dysplasia Treatment Market by Distribution Channel
- 3.4.1: Hospitals Pharmacies
- 3.4.2: Retail Pharmacies
- 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Fibromuscular Dysplasia Treatment Market by Region
4.2: North American Fibromuscular Dysplasia Treatment Market
- 4.2.1: North American Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
- 4.2.2: North American Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
4.3: European Fibromuscular Dysplasia Treatment Market
- 4.3.1: European Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
- 4.3.2: European Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
4.4: APAC Fibromuscular Dysplasia Treatment Market
- 4.4.1: APAC Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
- 4.4.2: APAC Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies
4.5: ROW Fibromuscular Dysplasia Treatment Market
- 4.5.1: ROW Fibromuscular Dysplasia Treatment Market by Drug Class: Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, Diuretics, Calcium Channel Blockers, Beta-Blockers, and Others
- 4.5.2: ROW Fibromuscular Dysplasia Treatment Market by Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Drug Class
- 6.1.2: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Distribution Channel
- 6.1.3: Growth Opportunities for the Global Fibromuscular Dysplasia Treatment Market by Region
6.2: Emerging Trends in the Global Fibromuscular Dysplasia Treatment Market
6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Fibromuscular Dysplasia Treatment Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Fibromuscular Dysplasia Treatment Market
- 6.3.4: Certification and Licensing